Novel combination of anticholineric and beta mimetics for the treatment of respiratory diseases

Abstract

The present invention describes a combination of anticholinergic and β mimetics for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma. It further comprises the preparation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.

1 - 23 . (canceled)  
     
     
         24 . A combination of R,R-glycopyrrolate or a physiologically acceptable salt thereof and a long-acting β2-mimetic agent for the treatment of respiratory diseases, especially of inflammatory or obstructive diseases.  
     
     
         25 . The combination according to  claim 24  wherein the β2-mimetic agent is selected from the group consisting of formoterol and salmeterol and their physiologically acceptable salts.  
     
     
         26 . The combination according to  claim 25  wherein the β2-mimetic agent is formoterol or a physiologically acceptable salt thereof.  
     
     
         27 . The combination of  claim 26 , wherein the daily dose of formoterol is from 1 to  72 μg.    
     
     
         28 . The combination according to  claim 25  wherein the β2-mimetic agent is salmeterol or a physiologically acceptable salt thereof.  
     
     
         29 . The combination of  claim 28 , wherein the daily dose of salmeterol is from 10 to 300 μg.  
     
     
         30 . The combination according to  claim 24 , wherein the daily dose of R,R-glycopyrrolate is from 5 to 500 μg.  
     
     
         31 . The combination according to  claim 24 , wherein the daily dose of R,R-glycopyrrolate is from 5 to 100 μg.  
     
     
         32 . A pharmaceutical for the treatment of allergies and respiratory diseases containing as active substances R,R-glycopyrrolate or a physiologically acceptable salt thereof and at least a long-acting β2 sympathomimetic.  
     
     
         33 . The pharmaceutical according to  claim 32  that comprises R,R-glycopyrrolate and formoterol or their physiologically acceptable salts.  
     
     
         34 . The pharmaceutical according to  claim 33 , wherein the active substances are available readily mixed in a fixed combination, if appropriate together with the usual excipients, adjuncts, and additives in a pharmaceutical form suitable for inhalative application.  
     
     
         35 . The pharmaceutical according to  claim 33 , where the active substances are available in separate packaging units whereby both substances can be taken from the separate packaging units in such a way that they are available for simultaneous inhalative application.  
     
     
         36 . The pharmaceutical according to  claim 35 , wherein the active substances can be administered independently from each other.  
     
     
         37 . The pharmaceutical according to  claim 32  that is an inhalable aerosol with or without propellant.  
     
     
         38 . The pharmaceutical according to  claim 32  that is an inhalable dry powder.  
     
     
         39 . The pharmaceutical according to  claim 32  that is an inhalable suspension or solution.  
     
     
         40 . The pharmaceutical according to  claim 32  presented in an inhaler.  
     
     
         41 . The pharmaceutical according to  claim 40  comprising formoterol as β2 sympathomimetic.  
     
     
         42 . The pharmaceutical according to  claim 40  comprising salmeterol as β2 sympathomimetic.  
     
     
         43 . The combination of  claim 27  wherein the daily dose is from 3 to 50 μg.  
     
     
         44 . The combination of  claim 43  wherein the daily dose is from 6 to 48 μg.  
     
     
         45 . The combination of  claim 29  wherein the daily dose is from 25 to 200 μg.  
     
     
         46 . The combination of  claim 45  wherein the daily dose is from 50 to 200 μg.  
     
     
         47 . The combination of  claim 30  wherein the daily dose is from 15 to 300 μg.